Aschoff H H, Clausen A, Tsoumpris K, Hoffmeister T
Klinik für Plastische, Hand- und Rekonstruktive Chirurgie, Sana Kliniken Lübeck, Kronsforder Allee 71-73, 23558, Lübeck, Deutschland.
Oper Orthop Traumatol. 2011 Dec;23(5):462-72. doi: 10.1007/s00064-011-0054-6.
Improvement of function following above-knee amputation with an osseointegrated, transcutaneous femoral implant as a hard point for the exo prosthesis, the so-called endo-exo femur prosthesis (EEFP).
Above knee amputation following trauma, tumor, or infection.
Diabetes, PAOD, psychiatric diseases, use of chemotherapeutic or corticosteroid medication, nonconcluded bone growth, lack of compliance, and florid infection at the time of implantation.
Performed as a two-step procedure: Stage 1 (implantation): sharp dissection of the end of the residual bone, adequate access to the intramedullar canal, cortical reaming using curettes and a flexible drill followed by cement-free, press-fit implantation of the endoprosthesis itself, closing of the soft tissue coat of the femur stump to reduce the risk of infection, assurance of primary and secondary stability via the metal spongiosa-like surface of the implant (Spongiosa Metal 2®). Stage 2 (exteriorization): 6 weeks postoperatively, opening of the skin at the distal point of the femur stump, the soft tissue between the skin and endoprosthesis is then removed and the double conus and the connecting adapter for the exoprothesis is attached.
Ascending weight bearing depending on bone quality. On average, full weight bearing can be achieved 8-10 weeks after stage 1 surgery.
The first endo-exo femur prosthesis (EEFP) was implanted in 1999. Through December 2009, 39 cases were operated in Lübeck, early serosanguinous drainage, soft tissue problems at the stoma, and ascending infections after mobilization of the patients could be minimized by further development of the design of the EEFP. Intramedullary infections were the exception (1 of 39 patients). A total of 4 explantations had to be performed (3 due to infection and 1 due to prosthetic failure). Two of those patients were again provided with an EEFP. Overall, the EEFP improved the gait pattern because of the bone-guided transmission of muscle power, increased osseoperception, and improved economical energy balance. Of the 39 patients, 37 said that they would again undergo operation.
使用骨整合式经皮股骨植入物作为外骨骼假肢的硬连接点,即所谓的内外侧股骨假体(EEFP),改善膝上截肢后的功能。
创伤、肿瘤或感染后膝上截肢。
糖尿病、外周动脉疾病、精神疾病、使用化疗或皮质类固醇药物、骨生长未完成、依从性差以及植入时存在急性感染。
分两步进行:第1阶段(植入):锐性解剖残留骨末端,充分进入髓腔,使用刮匙和柔性钻头进行皮质扩孔,然后无骨水泥、压配式植入内置假体本身,闭合股骨残端的软组织包膜以降低感染风险,通过植入物的金属海绵状表面(Spongiosa Metal 2®)确保一期和二期稳定性。第2阶段(外置):术后6周,在股骨残端远端切开皮肤,然后切除皮肤与内置假体之间的软组织,并连接双圆锥体和外骨骼假肢的连接适配器。
根据骨质逐渐增加负重。平均而言,在第1阶段手术后8 - 10周可实现完全负重。
1999年首次植入内外侧股骨假体(EEFP)。截至2009年12月,吕贝克共进行了39例手术,通过进一步改进EEFP的设计,可将早期血清样引流、造口处软组织问题以及患者活动后逐渐出现的感染降至最低。髓内感染为例外情况(39例患者中有1例)。总共进行了4次取出手术(3次因感染,1次因假体故障)。其中2例患者再次植入了EEFP。总体而言,由于肌肉力量的骨传导、骨感知增加以及经济能量平衡改善,EEFP改善了步态模式。39例患者中,37例表示愿意再次接受手术。